Abstract 1859P
Background
Cognitive impairment (CI) is a common late effect after cancer treatment, for which effective treatment is lacking. Goal Management Training (GMT) is a validated cognitive remediation protocol reported to improve cognition including perceived daily life executive functioning, in neurological conditions. However, GMT has never been examined in cancer survivors, nor been presented in a digital format. This study examined the feasibility and acceptability of digital GMT in cervical cancer survivors (CCS) with subjective and/or objective CI.
Methods
We invited 65 CCS with CI to participate. Participants were randomized in a 1:1 ratio between digital GMT and a computerized cognitive training (CCT) program (BrainHQ). GMT consists of six weekly group-based modules encompassing discussion of participants’ real-life cognitive deficits, practice on tasks of attention and self-monitoring, as well as homework assignments. BrainHQ is a web-based training platform with exercises targeting several cognitive domains. For six weeks, participants joined digital training sessions of one hour twice a week. The primary endpoint was attendance, and participants attending ≥80% of the sessions were categorized as completers. Acceptability was evaluated 1 week post-intervention using the Client Satisfaction Questionnaire-8 (CSQ-8). A total CSQ-8 score ≥ 26 was defined as “very satisfied”, scores 20-25 as “satisfied”, and scores <20 as “not satisfied”.
Results
33 CCS with a median age of 50.0 years (range 35-67) were randomized to either GMT (N = 16) or CCT (N = 17). In the GMT group, all participants completed the intervention (100%), compared to 15 (88%) in the CCT group. Median CSQ-8 in the GMT and CCT group was 25 (SD 3.7, range 18-31) and 24 (SD 3.1, range 19-30) respectively. Participants in both groups reported a high level of satisfaction as 40% reported being “very satisfied” and 53% “satisfied”.
Conclusions
A digital cognitive training program such as GMT is feasible with a high level of compliance and satisfaction in CCS and is suitable to be tested in a larger study. Exploratory analyses of neuropsychological assessments in our study will provide important preliminary data on the efficacy of improving cognitive function in CCS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jan Kåre Heiberg and Marthe Vildåsen.
Disclosure
K. lindemann: Financial Interests, Institutional, Research Grant, Grants or contracts, paid to institution: GSK; Financial Interests, Institutional, Advisory Board, Participation on Data Safety Monitoring/advisory board: Eisai, MSD, Nycode, AstraZeneca, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05